Alcohol septal ablation in hypertrophic cardiomyopathy

Authors

  • Juan José Santos Mateo Hospital Virgen del Castillo, Yecla, Murcia, Spain
  • Juan R Gimeno Hospital Universitario Virgen de La Arrixaca, El Palmar, Murcia, Spain

DOI:

https://doi.org/10.21542/gcsp.2018.30

Abstract

Alcohol septal ablation (ASA) has become an alternative to surgical myectomy in obstructive hypertrophic cardiomyopathy since it was first introduced in 1994 by Sigwart. The procedure alleviates symptoms by producing a limited infarction of the upper interventricular septum, resulting in a decrease in left ventricular outflow tract (LVOT) gradient. The technique has been improved over time and the results are comparable with those of myectomy. Initial concerns about long-term outcomes have been largely resolved. In this review, we discuss indications, technical aspects, clinical results and patient selection to ASA.

Downloads

Published

2018-10-24

Issue

Vol. 2018 No. 3 (2018)

Section

Review articles

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.